



## Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences

January 29, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 29, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced it will participate in two investor conferences in February:

- Canaccord Genuity Rare Disease, BioPharma One-on-One Day on Tuesday, Feb. 2, 2016 in New York, NY.
- Leerink Partners Global Healthcare Conference on Feb. 10 – 11, 2016 in New York, NY.

Roger Pomerantz, M.D., Chairman, President and CEO of Seres, will participate in a question and answer session on the first day of the Leerink Partners Global Healthcare Conference. The session will be available under the Investors and Media section of Seres' website at [www.serestherapeutics.com](http://www.serestherapeutics.com). A replay of the session will become available approximately one hour after the event and will be archived on the site for 21 days.

### About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome characterized by an increased presence of pathogenic bacterial species, where the natural state of bacterial diversity is imbalanced. Seres' most advanced program, SER-109, has successfully completed a Phase 1b/2 study demonstrating a clinical benefit in patients with recurring *Clostridium difficile* infection (CDI) and is currently being evaluated in a Phase 2 study in recurring CDI. The FDA has granted SER-109 Orphan Drug, as well as Breakthrough Therapy, designations. Seres' second clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC).

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160129005817/en/>

Source: Seres Therapeutics, Inc.

### IR Contact:

Seres Therapeutics  
Carlo Tanzi, Ph.D., 617-203-3467  
Head of Investor Relations and Corporate Communications  
[Ctanzi@serestherapeutics.com](mailto:Ctanzi@serestherapeutics.com)

or

### PR Contact:

Ten Bridge Communications  
Dan Quinn, 781-475-7974  
[Dan@tenbridgecommunications.com](mailto:Dan@tenbridgecommunications.com)